Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum including water-soluble chewing gum ingredients and water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the water-soluble chewing gum ingredients include one or more sugar alcohols in an amount of 35-80% by weight of the chewing gum, and wherein the chewing gum has one or more cannabinoids.

Abstract: The present invention is directed to a flowable hemostatic paste comprising a crosslinked carboxymethyl cellulose and at least one non-toxic dispersant. More specifically the present invention relates to a hemostatic paste containing citric acid cross-linked CMC, which is suspended or dispersed as a powder in a mixture of a first non-toxic glycerol-containing hygroscopic dispersant and a second non-toxic alcohol functionalized dispersant comprising propylene glycol or 1,3-butanediol.

Abstract: The invention relates to a pasty preparation for forming a semirigid dressing, said preparation having the following formulation: 30-70% by weight water, 1-10% by weight gelling agent, 10-40% by weight glycerol or polyvalent alcohols, in particular propylene glycol or sorbitol, 0-30% by weight oil, 0.5-5% by weight water-soluble salts, 0.5-2% by weight rheological fillers, and 1-5% adsorbent fillers.

Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.

Abstract: Provided herein are, inter alia, methods of treating red blood cell disorders and cancer using anti-miR126 compounds. The methods include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence to treat red blood cell disorders. Other methods provided herein include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence and a tyrosine kinase inhibitor to treat cancer.

Abstract: A composition and method for administration to a domesticated animal having heartworm disease includes proportionate amounts of water, acidified copper sulfate, potassium permanganate, and a flavoring agent or binder such as salt.

Abstract: Topical formulations comprising a dipeptide having a sequence of Lys-Pro, optionally complexed with an amino add, and at least one bioflavonoid or bioflavonoid extract in a cosmetically or pharmaceutically acceptable carrier provide intense skin hydration and improve skin texture and appearance.

Abstract: Disclosed are compositions and methods for the co-delivery of ribonucleic acids and interferon binding proteins. Compositions include mineral coated microparticles having a mineral layer, a ribonucleic acid, and an interferon binding protein. Ribonucleic acids and interferon binding proteins can be adsorbed to the mineral layer, can be incorporated into the mineral Layer, and combinations thereof. Also disclosed are methods for co-delivery of ribonucleic acids and interferon binding proteins and methods for treating inflammatory diseases using mineral coated microparticles having a mineral layer to provide co-delivery of ribonucleic acids and interferon binding proteins.

Abstract: A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.

Abstract: In various embodiments, the present invention is directed to a degradable poly(ester urea) (PEU)-based adhesion barrier, particularly suitable for use in connection with surgical mesh repair in the treatment of hernias and other soft tissue injuries comprising an amino acid based poly(ester urea) backbone and one or more zwitterionic side chains connected to the amino acid based poly(ester urea) backbone through a sulfide bond. In some other embodiments, the present invention is directed to method of making the PEU-based adhesion barriers comprising: preparing an amino acid based PEU polymer or terpolymer having one or more allyl functional groups; preparing a thiol functionalized zwitterionic compound; and reacting the allyl functionalized PEU polymer or terpolymer with the thiol functionalized zwitterionic compound to form a degradable PEU-based adhesion barrier having an amino acid based PEU backbone having zwitterionic side chains.

Abstract: This invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one microcapsule comprising at least: —a core, —a first laminated coating surrounding said core comprising at least 45% by weight of the total weight, of a microcapsule of multilayer interference particles comprising at least one iron oxide, and —a second laminated coating surrounding said first coating, comprising between 10 and 40% by weight of titanium dioxide relative to the total weight of a microcapsule, said multilayer interference particles being released from said microcapsule(s) only when said composition is applied on a keratin material such as keratin fibers or the skin.

Abstract: Embodiments provide an apparel product. The apparel product includes a major component forming a base portion of the apparel product and is configured to be supported and worn at least partially over a portion of a wearer. The apparel product includes a minor component forming a secondary portion configured to be coupled to the major component. An adhesive is disposed at least partially between a portion of the major component and a portion of the minor component. The adhesive includes a shape memory material.

Abstract: A polymeric material fiber includes a polymeric material which is a homopolymer of caprolactone or a copolymer of at least 90% by weight of caprolactone and one or more additional monomers. An implantable mesh includes this fiber alone or combined with one or more additional fiber materials. Methods for treating patients involve implanting the fiber material, for example incorporated in a mesh.

Abstract: Stable, solid triamine compositions are disclosed. The pressed, cast, extruded or other solid compositions are suitable for antimicrobial, sanitizing and disinfectant applications. Ready-to-use solutions are obtained by dissolving the solid triamine compositions with water and the methods of use thereof are particularly suitable for cleaning, disinfecting, sanitizing, rinsing and/or lubricating. Beneficially, the solid triamine compositions are at least partially neutralized, allowing activity of 90% and greater of the biocidal triamine, and provide at least substantially similar or superior performance and micro efficacy to liquid formulations.

Abstract: Alprazolam formulated as an inhaled condensation aerosol and method for treating epilepsy and/or seizures.

Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be infected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

Abstract: The invention relates to a hemostatic composition comprising a mixture of cellulose-based short and long fibers, preparation and use thereof.

Abstract: Lip compositions including at least one semi-crystalline acrylate copolymer, wherein the compositions include at least two components prior to mixing and application to lips and are capable of forming a multilayer structure after application to lips, are provided.

Abstract: Cosmetic compositions capable of forming a multilayer structure after application to a keratinous material are provided, as well as methods of applying such compositions to a keratinous material.